Janine Schuurman

Janine Schuurman leads the scientific organization at Genmab, where she has been instrumental in developing the DuoBody bispecific antibody platform based on controlled Fab-arm exchange, enabling the efficient generation of bispecific antibodies from two parental IgG1 antibodies. This technology has produced multiple clinical-stage bispecific antibodies including epcoritamab for lymphoma, which received FDA approval. Her work on the HexaBody platform for enhancing complement-dependent cytotoxicity represents another innovative approach to engineering antibody effector function.